Molecular Diagnostics Partnering Terms and Agreements, New Report Launched

The Molecular Diagnostics Partnering Terms & Agreements provides comprehensive understanding and unprecedented access to the molecular diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Description

The Molecular Diagnostics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest molecular diagnostics agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all molecular diagnostics partnering deals announced since 2009 including financial terms where available including over 300 links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What are the precise rights granted or optioned?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading molecular diagnostics deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in molecular diagnostics partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by molecular diagnostics partnering company A-Z , deal type definitions and molecular diagnostics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about molecular diagnostics partnering in the research, development and commercialization of molecular diagnostics technologies and products.

Report scope

Molecular Diagnostics Partnering Agreements is intended to provide the reader with an in-depth understanding and access to molecular diagnostics trends and structure of deals entered into by leading companies worldwide.

Molecular Diagnostics Partnering Agreements includes:

Trends in molecular diagnostics dealmaking in the biopharma industry since 2009

• Analysis of molecular diagnostics deal structure
• Access to headline, upfront, milestone and royalty data
• Access to over 300 molecular diagnostics deal records
• The leading molecular diagnostics deals by value since 2009

In Molecular Diagnostics Partnering Agreements, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific diagnostics technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Molecular Diagnostics Partnering Agreements report provides comprehensive access to available deals and contract documents for over 300 molecular diagnostics deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Molecular Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of molecular diagnostics deal trends since 2009
• Access molecular diagnostics deal headline, upfront, milestone and royalty data
• Analysis of the structure of molecular diagnostics agreements with numerous real life case studies
• Comprehensive access to over 300 links to actual infectious vaccines deals entered into by the world’s biopharma companies, together with real world clause examples
• Identify leading molecular diagnostics deals by value since 2009
• Identify the most active molecular diagnostics dealmakers since 2009
• Insight into the terms included in molecular diagnostics agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 432 pages, “Molecular Diagnostics Partnering Terms and Agreements” report covering the Introduction, Trends in molecular diagnostics dealmaking, Leading molecular diagnostics deals, Big pharma molecular diagnostics deals, Big biotech molecular diagnostics deals, Molecular diagnostics partnering contracts directory, Molecular diagnostics dealmaking directory, Appendices. The report covered companies are - Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Pfizer, Novartis, GSK, Takeda, Bayer, Boehringer Ingelheim

Know more about this report at – http://mrr.cm/ZDf

Find all Pharma and Healthcare Technology Reports at: 

http://www.marketresearchreports.com/pharma-healthcare-technology